MedTrace Logo

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT04947423 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-09-17

No results posted yet for this study

Summary

This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion

Conditions

Interventions

DRUG

DPI-386 Nasal Gel

Subjects will self-administer DPI-386 Nasal Gel or Placebo

DRUG

Placebo

Subjects will self-administer DPI-386 Nasal Gel or Placebo

Sponsors & Collaborators

  • Defender Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Repurposed Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • David Helton · Defender Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-14
Primary Completion
2021-08-12
Completion
2021-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947423 on ClinicalTrials.gov